MT1988: Phase 2 Insights in Identifying & Treating Cognitive Impairment in Schizophrenia
- Exploring digital biomarker driven stratification, based on cognitive measures, to move toward biologically homogeneous patient groups and reduce trial heterogeneity
- Investigating a fixed dose combination approach to nicotinic agonism to improve working memory and attentional deficits relevant to a range of neuropsychiatric disorders
- Advancing the first Phase 2 study to target the clinical high risk for psychosis population
- Leveraging the high profile Accelerating Medicines Partnership for Schizophrenia to identify individuals most likely to benefit from early intervention